正在加载视频...

视频加载失败

加载此视频时出现问题。这可能是由于临时网络问题，或视频可能不可用。

A new review summarizes cardiac physiologic pacing for heart failure, highlighting benefits of biventricular pacing and emerging evidence for His-bundle and left bundle-branch pacing to improve function and outcomes. Read the Review Article “Physiologic Pacing in Heart Failure” by Mihail G. Chelu, MD, PhD, MD, PhD, Jeanne E. Poole,... show more

NEJM

980,913 subscribers

13,744 次观看 • 6 个月前 •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

Sudden cardiac arrest in athletes may be attributable to cardiac and noncardiac causes. With diagnosis and treatment, a return to play may be reasonable. Prevention, emergency planning, and shared decision making are key. Learn more in the Review Article “Sudden Cardiac Arrest in Athletes” by Rachel Lampert, MD, and Kimberly G. Harmon, MD (Kimberly Harmon ), from Yale School of Medicine and the University of Washington (University of Washington):

Sudden cardiac arrest in athletes may be attributable to cardiac and noncardiac causes. With diagnosis and treatment, a return to play may be reasonable. Prevention, emergency planning, and shared decision making are key. Learn more in the Review Article “Sudden Cardiac Arrest in Athletes” by Rachel Lampert, MD, and Kimberly G. Harmon, MD (Kimberly Harmon ), from Yale School of Medicine and the University of Washington (University of Washington):

NEJM

14,590 次观看 • 6 个月前

Cardiogenic shock is defined as a cardiac disorder that results in both clinical and biochemical evidence of sustained tissue hypoperfusion. Learn more about the management and diagnosis of this disorder in the Review Article “Cardiogenic Shock” by Holger Thiele, MD (Holger Thiele), and Christian Hassager, MD, from Heart Center Leipzig at Leipzig University, Leipzig Heart Science, Rigshospitalet, and the University of Copenhagen (Københavns Uni):

Cardiogenic shock is defined as a cardiac disorder that results in both clinical and biochemical evidence of sustained tissue hypoperfusion. Learn more about the management and diagnosis of this disorder in the Review Article “Cardiogenic Shock” by Holger Thiele, MD (Holger Thiele), and Christian Hassager, MD, from Heart Center Leipzig at Leipzig University, Leipzig Heart Science, Rigshospitalet, and the University of Copenhagen (Københavns Uni):

NEJM

13,460 次观看 • 6 个月前

Peripheral artery disease is linked to cardiovascular risk and impaired mobility. Diagnosis relies on ankle–brachial index testing, and management involves cardiovascular risk reduction, exercise, and selective revascularization. Learn more in the Clinical Practice article “Peripheral Artery Disease in the Legs” by Mary M. McDermott, MD, from the Northwestern University Feinberg School of Medicine (Northwestern Feinberg School of Medicine):

Peripheral artery disease is linked to cardiovascular risk and impaired mobility. Diagnosis relies on ankle–brachial index testing, and management involves cardiovascular risk reduction, exercise, and selective revascularization. Learn more in the Clinical Practice article “Peripheral Artery Disease in the Legs” by Mary M. McDermott, MD, from the Northwestern University Feinberg School of Medicine (Northwestern Feinberg School of Medicine):

NEJM

13,053 次观看 • 5 个月前

Race-based pulmonary-function test (PFT) guidelines were taught to clinicians for decades, even as questions arose about their validity and the implications of their use. Rohan Khazanchi, MD, MPH (Rohan Khazanchi, MD, MPH), who coauthored a recent Medicine and Society article on race-based PFTs, discusses their financial implications and their adverse consequences. Read the article and watch the full video podcast with host Harleen Marwah, MD (Harleen Marwah, MD, MS):

Race-based pulmonary-function test (PFT) guidelines were taught to clinicians for decades, even as questions arose about their validity and the implications of their use. Rohan Khazanchi, MD, MPH (Rohan Khazanchi, MD, MPH), who coauthored a recent Medicine and Society article on race-based PFTs, discusses their financial implications and their adverse consequences. Read the article and watch the full video podcast with host Harleen Marwah, MD (Harleen Marwah, MD, MS):

NEJM

18,506 次观看 • 10 个月前

The Aberdeen knot 🪢 was called that way when Sir James Learmonth at University of Aberdeen UoA Medicine, Medical Sciences and Nutrition use it because he noted that it used less thread than the surgeon’s knot and now is the ideal knot for end a closure of a laparotomy! #SoMe4Surgery Ron Barbosa MD FACS Steven D Wexner MD, PhD Paula Ferrada MD FACS FCCM MAMSE

The Aberdeen knot 🪢 was called that way when Sir James Learmonth at University of Aberdeen UoA Medicine, Medical Sciences and Nutrition use it because he noted that it used less thread than the surgeon’s knot and now is the ideal knot for end a closure of a laparotomy! #SoMe4Surgery Ron Barbosa MD FACS Steven D Wexner MD, PhD Paula Ferrada MD FACS FCCM MAMSE

Dr Luis Felipe Cabrera Vargas MD FACS

65,857 次观看 • 3 年前

In this episode of the Better Edge podcast, S. Christopher Malaisrie, MD, surgical director of the Northwestern Medicine Center for Heart Valve Disease, discusses patient selection, technical expertise needed, homograft and autograft failure, and advances on the horizon for the Ross procedure.

In this episode of the Better Edge podcast, S. Christopher Malaisrie, MD, surgical director of the Northwestern Medicine Center for Heart Valve Disease, discusses patient selection, technical expertise needed, homograft and autograft failure, and advances on the horizon for the Ross procedure.

NM Cardiovascular

162,770 次观看 • 3 年前

One of the happiest moments of my life! To see my son graduate with honors from Medical School (University of Illinois College of Medicine, Chicago).❤️ And was Vice-President of the Class Board for all 4 years! Ready for his next chapter… Internal Medicine Residency at Northwestern Memorial Hospital (McGaw Medical Center of Northwestern University Feinberg School of Medicine in Chicago)! Hector, we are so proud of you!!!🥰😘🙏Hector Cajigas, MD Hector Cajigas Mayo Clinic CV

One of the happiest moments of my life! To see my son graduate with honors from Medical School (University of Illinois College of Medicine, Chicago).❤️ And was Vice-President of the Class Board for all 4 years! Ready for his next chapter… Internal Medicine Residency at Northwestern Memorial Hospital (McGaw Medical Center of Northwestern University Feinberg School of Medicine in Chicago)! Hector, we are so proud of you!!!🥰😘🙏Hector Cajigas, MD Hector Cajigas Mayo Clinic CV

Mayra Guerrero, MD

34,356 次观看 • 2 年前

THE OncoAlert 🚨 VJ Oncology Journal Club A Great Pleasure to have Misty Dawn Shields 🇺🇸of The Shields Lab Guides us through her paper out on ACS Journal Cancer TOP ADVANCES in #SCLC 🫁 #LungCancer Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group SmallCellSMASHERS , offer new support for patients with this historically stigmatized disease. Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA Co Authors Lauren Averett Byers, MD Anne Chiang Lung Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD, FASCO Bartomeu Massuti Dr. Antonio Calles 🫁🚭 Sébastien Couraud 🫁🚭🌍 Solange Peters Umberto Malapelle Giannis Mountzios Charu Aggarwal, MD, MPH, FASCO Christine Lovly, MD, PhD, FASCO Jill Feldman Ben Solomon Vanita Noronha, MBBS MD DM Sanjay Popat Jordi Remon Jarushka Naidoo Martin Reck Dr. Estela Rodriguez Julien Mazieres TerriConneran #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD

THE OncoAlert 🚨 VJ Oncology Journal Club A Great Pleasure to have Misty Dawn Shields 🇺🇸of The Shields Lab Guides us through her paper out on ACS Journal Cancer TOP ADVANCES in #SCLC 🫁 #LungCancer Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group SmallCellSMASHERS , offer new support for patients with this historically stigmatized disease. Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA Co Authors Lauren Averett Byers, MD Anne Chiang Lung Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD, FASCO Bartomeu Massuti Dr. Antonio Calles 🫁🚭 Sébastien Couraud 🫁🚭🌍 Solange Peters Umberto Malapelle Giannis Mountzios Charu Aggarwal, MD, MPH, FASCO Christine Lovly, MD, PhD, FASCO Jill Feldman Ben Solomon Vanita Noronha, MBBS MD DM Sanjay Popat Jordi Remon Jarushka Naidoo Martin Reck Dr. Estela Rodriguez Julien Mazieres TerriConneran #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD

OncoAlert

14,778 次观看 • 1 年前

DID A THING TODAY!! Thank you God and thank you Howard University! My time with Howard University College of Medicine 2023 has been the most rewarding!! ✨ Jessica R. Smith, MD has a nice ring to it ✨

DID A THING TODAY!! Thank you God and thank you Howard University! My time with Howard University College of Medicine 2023 has been the most rewarding!! ✨ Jessica R. Smith, MD has a nice ring to it ✨

Jessica Smith

17,246 次观看 • 3 年前

Dear Colleagues at #ASCO25 Honored to introduce Dr. Matthias Preusser🇦🇹 of the Medical University of Vienna who just Presented Results from the TUXEDO-3 Trials with a concomitant publication in Nature Medicine Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial Leptomeningeal metastatic disease (LMD) is a devastating complication of solid tumors with limited treatment options. In cohort 3 of the phase 2 TUXEDO-3 trial, the antibody–drug conjugate patritumab deruxtecan (HER3-DXd) was evaluated for safety and efficacy in 20 patients with LMD from solid cancers, primarily #BreastCancer (60%) and🫁 #LungCancer (30%). Patients received HER3-DXd every three weeks, and after a median follow-up of 5.4 months, 65% were alive at 3 months, meeting the primary endpoint. The 3- and 6-month overall survival rates were 69.6% and 58.9%, respectively, with intracranial and extracranial clinical benefit rates of 50.0% and 38.5%. Neurological symptoms and quality of life remained stable or improved, with no new neurological toxicities. The most common adverse events were generally manageable, supporting HER3-DXd as a promising therapeutic option for patients with LMD. Lung Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD, FASCO Bartomeu Massuti Dr. Antonio Calles 🫁🚭 Solange Peters Umberto Malapelle Christine Lovly, MD, PhD, FASCO Jill Feldman Ben Solomon Sanjay Popat Jordi Remon Jarushka Naidoo Dr. Estela Rodriguez Julien Mazieres Breast Matteo Lambertini, MD PhD Philippe Aftimos, MD  Evandro de Azambuja, MD, PhD 𝙅𝙚𝙨𝙪𝙨 𝘼𝙣𝙖𝙢𝙥𝙖 𝙈.𝘿, 𝙈.𝙎🧬🔬 Erika Hamilton, MD Dr. Kelly Shanahan Stacey Tinianov (she/her) MPH, BCPA Julia Maués Maryam Lustberg MD, MPH, FASCO IBC Research Fdn Roberta A Albany Hope Rugo Sara Tolaney Sherene Loi, MD Javier Cortes MD PhD Janice Cowden #OncoAlertAF Dra. María Natalia Gandur Quiroga Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD MEDSIR

Dear Colleagues at #ASCO25 Honored to introduce Dr. Matthias Preusser🇦🇹 of the Medical University of Vienna who just Presented Results from the TUXEDO-3 Trials with a concomitant publication in Nature Medicine Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial Leptomeningeal metastatic disease (LMD) is a devastating complication of solid tumors with limited treatment options. In cohort 3 of the phase 2 TUXEDO-3 trial, the antibody–drug conjugate patritumab deruxtecan (HER3-DXd) was evaluated for safety and efficacy in 20 patients with LMD from solid cancers, primarily #BreastCancer (60%) and🫁 #LungCancer (30%). Patients received HER3-DXd every three weeks, and after a median follow-up of 5.4 months, 65% were alive at 3 months, meeting the primary endpoint. The 3- and 6-month overall survival rates were 69.6% and 58.9%, respectively, with intracranial and extracranial clinical benefit rates of 50.0% and 38.5%. Neurological symptoms and quality of life remained stable or improved, with no new neurological toxicities. The most common adverse events were generally manageable, supporting HER3-DXd as a promising therapeutic option for patients with LMD. Lung Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD, FASCO Bartomeu Massuti Dr. Antonio Calles 🫁🚭 Solange Peters Umberto Malapelle Christine Lovly, MD, PhD, FASCO Jill Feldman Ben Solomon Sanjay Popat Jordi Remon Jarushka Naidoo Dr. Estela Rodriguez Julien Mazieres Breast Matteo Lambertini, MD PhD Philippe Aftimos, MD  Evandro de Azambuja, MD, PhD 𝙅𝙚𝙨𝙪𝙨 𝘼𝙣𝙖𝙢𝙥𝙖 𝙈.𝘿, 𝙈.𝙎🧬🔬 Erika Hamilton, MD Dr. Kelly Shanahan Stacey Tinianov (she/her) MPH, BCPA Julia Maués Maryam Lustberg MD, MPH, FASCO IBC Research Fdn Roberta A Albany Hope Rugo Sara Tolaney Sherene Loi, MD Javier Cortes MD PhD Janice Cowden #OncoAlertAF Dra. María Natalia Gandur Quiroga Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD MEDSIR

OncoAlert

11,511 次观看 • 1 年前

These are reprehensible comments from Hakeem Jeffries Dr. Oz is the most credentialed and accomplished CMS administrator in the history of the department. He is marshaling a bi-partisan conversation on how to reform a broken system instead of just spending more money. Would be nice for you to join this conversation instead of spewing toxic rhetoric. As a reminder, Mr. Jeffries, here are his credentials: ✅Earned a Bachelor of Arts in Biology from Harvard University (1982). ✅Earned a Doctor of Medicine (M.D.) degree from University of Pennsylvania School of Medicine. ✅Earned a Master of Business Administration (M.B.A.) from Wharton School of the University of Pennsylvania (in parallel with his M.D.). ✅Completed residency training in general surgery and subsequent fellowship training in cardiothoracic (heart and chest) surgery at New York‑Presbyterian Hospital/Columbia University Medical Center. ✅Served as Professor of Surgery at Columbia University College of Physicians and Surgeons and later became Professor Emeritus. ✅Took a leadership role in cardiac surgery and related innovations (including minimally invasive devices) during his clinical career. ✅Authored hundreds of peer-reviewed publications, book chapters and medical texts, contributing to academic and clinical medicine. ✅Holds board certification and membership in major professional societies for cardiac and thoracic surgery.

These are reprehensible comments from Hakeem Jeffries Dr. Oz is the most credentialed and accomplished CMS administrator in the history of the department. He is marshaling a bi-partisan conversation on how to reform a broken system instead of just spending more money. Would be nice for you to join this conversation instead of spewing toxic rhetoric. As a reminder, Mr. Jeffries, here are his credentials: ✅Earned a Bachelor of Arts in Biology from Harvard University (1982). ✅Earned a Doctor of Medicine (M.D.) degree from University of Pennsylvania School of Medicine. ✅Earned a Master of Business Administration (M.B.A.) from Wharton School of the University of Pennsylvania (in parallel with his M.D.). ✅Completed residency training in general surgery and subsequent fellowship training in cardiothoracic (heart and chest) surgery at New York‑Presbyterian Hospital/Columbia University Medical Center. ✅Served as Professor of Surgery at Columbia University College of Physicians and Surgeons and later became Professor Emeritus. ✅Took a leadership role in cardiac surgery and related innovations (including minimally invasive devices) during his clinical career. ✅Authored hundreds of peer-reviewed publications, book chapters and medical texts, contributing to academic and clinical medicine. ✅Holds board certification and membership in major professional societies for cardiac and thoracic surgery.

Calley Means

271,500 次观看 • 8 个月前

Recently, authors of the HHS review on pediatric gender dysphoria sat down with Jay Bhattacharya, MD, PhD to discuss the report and its significance. In this video, MIT philosopher Alex Byrne explains (with additional commentary from me) the language problems in gender medicine.

Recently, authors of the HHS review on pediatric gender dysphoria sat down with Jay Bhattacharya, MD, PhD to discuss the report and its significance. In this video, MIT philosopher Alex Byrne explains (with additional commentary from me) the language problems in gender medicine.

Leor Sapir

19,987 次观看 • 3 个月前

Three videos show echocardiography in a woman who presented with acute pain, swelling, and bruising on the upper portion of her left knee after using an electronic massage gun. Read the full case details in the Clinical Problem-Solving article “A Fruitful Workup” by N. Jain et al., from Penn Medicine and the University of Pennsylvania:

Three videos show echocardiography in a woman who presented with acute pain, swelling, and bruising on the upper portion of her left knee after using an electronic massage gun. Read the full case details in the Clinical Problem-Solving article “A Fruitful Workup” by N. Jain et al., from Penn Medicine and the University of Pennsylvania:

NEJM

19,778 次观看 • 10 个月前

More from Mahindra University… BDes students at the School of Design and Innovation work on live projects and one of them was the creation of merchandise for Ramoji Film City. The promoter and MD of Ramoji Film City, Smt Vijayeshwari visited the School to inaugurate and tour the end semester show… One of the enormous advantages of Mahindra University is its location in the middle of a wide ecosystem of business, technology, arts & entertainment…

More from Mahindra University… BDes students at the School of Design and Innovation work on live projects and one of them was the creation of merchandise for Ramoji Film City. The promoter and MD of Ramoji Film City, Smt Vijayeshwari visited the School to inaugurate and tour the end semester show… One of the enormous advantages of Mahindra University is its location in the middle of a wide ecosystem of business, technology, arts & entertainment…

anand mahindra

362,180 次观看 • 7 个月前

Honoring the tireless efforts of oncologists on the front lines of cancer research and care. This month, we're celebrating their achievements with a billboard in the heart of Times Square. Thank you for your unwavering commitment! #LARVOL #Oncology #TimesSquare #CancerCare Dr Amol Akhade | Vivek Subbiah, MD | Vinay Prasad MD MPH | Jeff Ryckman | Razelle Kurzrock, MD | Matt Spraker | Jon Trent, MD, PhD | Timothy Chan | Emil Lou, MD, PhD, FACP | Dr. Patrick Hwu | Arndt Vogel | Pashtoon Kasi MD, MS | Dr. Cathy Eng | Mike Pishvaian | Mark Lewis, MD, FASCO | Wafik S. El-Deiry, MD, PhD, FACP | Yelena Y. Janjigian MD | Sharlene Gill, MD, MPH, MBA, FASCO | Dr. Nina Niu Sanford | Rachna Shroff, MD, MS, FASCO | Myriam Chalabi | Tanios Bekaii-Saab, MD | Syed A. Ahmad | Ben Westphalen | Erman Akkus | ONCO BRUNO

Honoring the tireless efforts of oncologists on the front lines of cancer research and care. This month, we're celebrating their achievements with a billboard in the heart of Times Square. Thank you for your unwavering commitment! #LARVOL #Oncology #TimesSquare #CancerCare Dr Amol Akhade | Vivek Subbiah, MD | Vinay Prasad MD MPH | Jeff Ryckman | Razelle Kurzrock, MD | Matt Spraker | Jon Trent, MD, PhD | Timothy Chan | Emil Lou, MD, PhD, FACP | Dr. Patrick Hwu | Arndt Vogel | Pashtoon Kasi MD, MS | Dr. Cathy Eng | Mike Pishvaian | Mark Lewis, MD, FASCO | Wafik S. El-Deiry, MD, PhD, FACP | Yelena Y. Janjigian MD | Sharlene Gill, MD, MPH, MBA, FASCO | Dr. Nina Niu Sanford | Rachna Shroff, MD, MS, FASCO | Myriam Chalabi | Tanios Bekaii-Saab, MD | Syed A. Ahmad | Ben Westphalen | Erman Akkus | ONCO BRUNO

LARVOL

26,565 次观看 • 1 年前

Dr. Mehmet Oz is a cardiothoracic surgeon. Hakeem Jeffries is a bottom-dweller lawyer calling a cardiac surgeon, a rando. So let’s compare educational backgrounds … and you all decide who should be listened to. .Dr. Mehmet Oz has an extensive and prestigious educational background. 🔹Undergraduate degrees (dual majors)from Harvard University – A.B. (Biology), graduated magna cum laude in 1982 🔹Graduate/Professional degrees from University of Pennsylvania (UPenn) – Combined MD/MBA program: 🔺MD (Doctor of Medicine) from the Perelman School of Medicine, 1986 🔺MBA (Master of Business Administration) from The Wharton School, 1986 Additional notable training: - Completed his residency in general surgery at NewYork-Presbyterian Hospital/Columbia University (1986–1991). - Served as chief resident in his final year. - Completed a cardiothoracic surgery fellowship at Columbia. .Hakeem Jeffries has the following hum-drum educational background. 🔹Undergraduate from Binghamton University (State University of New York) 🔺B.A. in Political Science, magna cum laude, 1992 🔹Graduate degrees from: - Georgetown University 🔺Master’s in Public Policy (MPP), 1994 - New York University (NYU) School of Law 🔺Juris Doctor (J.D.), cum laude, 1997

Dr. Mehmet Oz is a cardiothoracic surgeon. Hakeem Jeffries is a bottom-dweller lawyer calling a cardiac surgeon, a rando. So let’s compare educational backgrounds … and you all decide who should be listened to. .Dr. Mehmet Oz has an extensive and prestigious educational background. 🔹Undergraduate degrees (dual majors)from Harvard University – A.B. (Biology), graduated magna cum laude in 1982 🔹Graduate/Professional degrees from University of Pennsylvania (UPenn) – Combined MD/MBA program: 🔺MD (Doctor of Medicine) from the Perelman School of Medicine, 1986 🔺MBA (Master of Business Administration) from The Wharton School, 1986 Additional notable training: - Completed his residency in general surgery at NewYork-Presbyterian Hospital/Columbia University (1986–1991). - Served as chief resident in his final year. - Completed a cardiothoracic surgery fellowship at Columbia. .Hakeem Jeffries has the following hum-drum educational background. 🔹Undergraduate from Binghamton University (State University of New York) 🔺B.A. in Political Science, magna cum laude, 1992 🔹Graduate degrees from: - Georgetown University 🔺Master’s in Public Policy (MPP), 1994 - New York University (NYU) School of Law 🔺Juris Doctor (J.D.), cum laude, 1997

C-Reason🇺🇸

56,340 次观看 • 8 个月前

VP of The American College of Pediatricians The American College of Pediatricians Jane Anderson MD: “Those puberty blockers are used in medicine to treat medical conditions and puberty is not a medical condition”

VP of The American College of Pediatricians The American College of Pediatricians Jane Anderson MD: “Those puberty blockers are used in medicine to treat medical conditions and puberty is not a medical condition”

Genspect

16,613 次观看 • 1 年前

Gratitude to Dr. Peter Ozuah, President and CEO of Montefiore Einstein Medicine, NY, for his 1 million dollars donation to build a new hostel for the College of Medicine, University of Ibadan.Thanks to the tireless work of the UCH Alumni Class of 1985,initiators of the project.

Gratitude to Dr. Peter Ozuah, President and CEO of Montefiore Einstein Medicine, NY, for his 1 million dollars donation to build a new hostel for the College of Medicine, University of Ibadan.Thanks to the tireless work of the UCH Alumni Class of 1985,initiators of the project.

abikedabiri

166,043 次观看 • 1 年前